#United States #Los Angeles #Schall Law Firm #Securities Fraud #Maravai LifeSciences

Reminder for Investors: Class Action Lawsuit Against Maravai LifeSciences Holdings

The Schall Law Firm, a renowned national firm specializing in investors' rights, has recently issued a reminder to shareholders of Maravai LifeSciences Holdings, Inc. regarding a significant opportunity to lead a class-action lawsuit. This legal action stems from alleged violations of the Securities Exchange Act of 1934, specifically, sections 10(b) and 20(a), along with Rule 10b-5 as stipulated by the U.S. Securities and Exchange Commission.

This advisory comes as a call to investors who acquired Maravai's securities during the defined period from August 7, 2024, to February 24, 2025. For those who experienced losses during this timeframe, it is crucial to act before the deadline of May 5, 2025.

If you are one of the affected shareholders, it is vital to reach out and participate in this lawsuit. Interested parties are encouraged to connect with Brian Schall from the Schall Law Firm located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Alternatively, investors can reach out via phone at 310-301-3335 or visit the firm’s website at www.schallfirm.com for further details. Email inquiries can also be sent to [email protected].

Context Behind the Lawsuit

The crux of the complaint centers around claims that Maravai LifeSciences misled investors with incorrect and unreliable information about its financial performance. Notably, the company is accused of failing to maintain appropriate internal controls over its financial reporting. Furthermore, it is alleged that Maravai recognized revenue incorrectly from specific transactions in the fiscal year 2024 and overstated its goodwill.

These accusations suggest that the company’s public declarations were not just misleading but materially false during the class period, contributing to significant investor losses when the truth was uncovered.

Investors should also be aware that, as of now, the class has yet to receive certification. This means that if you decide to take no action, you will remain an absent class member without representation from an attorney.

Why You Should Join the Lawsuit

Joining this class action offers a chance for affected investors to claim recompense for their losses. The Schall Law Firm is recognized for its commitment to protecting shareholder rights and has a proven track record of representing investors globally in securities class action cases.

Investors must take this opportunity seriously, as participating in the lawsuit could potentially restore a part of the losses incurred through the alleged misconduct of Maravai LifeSciences. With attorney fees likely to be contingent on a recovery, shareholders can pursue justice without upfront legal costs, making it a viable option for those who might feel uncertain about their financial future due to this situation.

Earlier, the firm has handled various cases and has effectively secured settlements for numerous clients, showcasing its expertise in navigating complex securities laws.

Next Steps for Investors

As the situation develops, shareholders should remain informed and proactive. Essential actions include:

• - Contacting legal experts at the Schall Law Firm for clarity on your rights and the process ahead.
• - Monitoring updates about the lawsuit and any significant developments regarding Maravai LifeSciences that may arise.
• - Consider filing to join the class action before the May 5 deadline to ensure your voice is heard in this pivotal case.

In conclusion, this is a crucial moment for investors in Maravai LifeSciences Holdings. It is a chance to pursue rightful compensation for potential losses incurred from securities fraud and misleading corporate declarations. Don’t miss the opportunity to join forces with fellow shareholders in seeking justice and restoration.